Royalty Days Sales Outstanding from 2010 to 2025

RPRX Stock  USD 31.59  0.36  1.13%   
Royalty Pharma Days Sales Outstanding yearly trend continues to be fairly stable with very little volatility. Days Sales Outstanding will likely drop to 126.25 in 2025. During the period from 2010 to 2025, Royalty Pharma Days Sales Outstanding regression line of annual values had r-squared of  0.20 and arithmetic mean of  126.72. View All Fundamentals
 
Days Sales Outstanding  
First Reported
2010-12-31
Previous Quarter
138.18
Current Value
126.25
Quarterly Volatility
12.14626957
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Royalty Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Royalty Pharma's main balance sheet or income statement drivers, such as Interest Expense of 226 M, Total Revenue of 2.8 B or Research Development of 57.5 M, as well as many indicators such as Price To Sales Ratio of 10.69, Dividend Yield of 0.0361 or PTB Ratio of 3.83. Royalty financial statements analysis is a perfect complement when working with Royalty Pharma Valuation or Volatility modules.
  
Check out the analysis of Royalty Pharma Correlation against competitors.

Latest Royalty Pharma's Days Sales Outstanding Growth Pattern

Below is the plot of the Days Sales Outstanding of Royalty Pharma Plc over the last few years. It is Royalty Pharma's Days Sales Outstanding historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Royalty Pharma's overall financial position and show how it may be relating to other accounts over time.
Days Sales Outstanding10 Years Trend
Slightly volatile
   Days Sales Outstanding   
       Timeline  

Royalty Days Sales Outstanding Regression Statistics

Arithmetic Mean126.72
Geometric Mean126.13
Coefficient Of Variation9.59
Mean Deviation9.97
Median134.31
Standard Deviation12.15
Sample Variance147.53
Range39.3328
R-Value(0.45)
Mean Square Error125.82
R-Squared0.20
Significance0.08
Slope(1.15)
Total Sum of Squares2,213

Royalty Days Sales Outstanding History

2025 126.25
2024 138.18
2023 120.15
2022 118.76
2021 108.83
2020 107.74
2019 98.85

About Royalty Pharma Financial Statements

Royalty Pharma investors use historical fundamental indicators, such as Royalty Pharma's Days Sales Outstanding, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Royalty Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Sales Outstanding 138.18  126.25 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Royalty Stock Analysis

When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.